Connecticut § 17a-673a Opioid use disorder treatment program requirements.

Connecticut Statutes

§ 17a-673a — Opioid use disorder treatment program requirements.

Connecticut § 17a-673a

Title 17aSocial and Human Services and Resources

Ch. 319jAddiction Services

This text of Connecticut § 17a-673a (Opioid use disorder treatment program requirements.) is published on Counsel Stack Legal Research, covering Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Conn. Gen. Stat. § 17a-673a (2026).

Text

(a)As used in this section:

(1)“Treatment program” means a program operated by the Department of Mental Health and Addiction Services or approved by the Commissioner of Mental Health and Addiction Services for treatment of the physical and psychological effects of drug dependency or for the detoxification of a drug-dependent person, as defined in section 17a-680 ;

(2)“Opioid use disorder” means a medical condition characterized by a problematic pattern of opioid use and misuse leading to clinically significant impairment or distress; and (3) “Opioid antagonist” means naloxone hydrochloride or any other similarly acting and equally safe drug approved by the federal Food and Drug Administration for the treatment of a drug overdose.

(b)A treatment program that provides treatment or detoxi

Free access — add to your briefcase to read the full text and ask questions with AI

(a) As used in this section: (1) “Treatment program” means a program operated by the Department of Mental Health and Addiction Services or approved by the Commissioner of Mental Health and Addiction Services for treatment of the physical and psychological effects of drug dependency or for the detoxification of a drug-dependent person, as defined in section 17a-680 ; (2) “Opioid use disorder” means a medical condition characterized by a problematic pattern of opioid use and misuse leading to clinically significant impairment or distress; and (3) “Opioid antagonist” means naloxone hydrochloride or any other similarly acting and equally safe drug approved by the federal Food and Drug Administration for the treatment of a drug overdose. (b) A treatment program that provides treatment or detoxification services to any person with an opioid use disorder shall (1) educate such person regarding opioid antagonists and the administration thereof at the time such person is admitted to or first receives services from such program, (2) offer education regarding opioid antagonists and the administration thereof to the relatives and significant other of such person if the relatives and significant other have been identified by such person, and (3) if there is a prescribing practitioner affiliated with such program who determines that such person would benefit from access to an opioid antagonist, issue a prescription for or deliver to such person at least one dose of an opioid antagonist at the time such person is admitted to or first receives treatment services from such program.